[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574266":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":36,"collaborators":40,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Asan Medical Center","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"HOJIN KIM, PI","cadiovascularthoracic surgery","STUDY_CHAIR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","82-2-3010-0506","rhonin.hojin@gmail.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"YUKYUNG CHOI, CRA","82-2-2045-3815","cyk1108@amc.seoul.kr",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":7,"country":27,"countryCode":7,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Seoul","SONGPA-GU","South Korea",{"type":29,"coordinates":30},"Point",[31,32],126.9784,37.566,{"lat":32,"lon":31},[35],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":7},{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","HO JIN KIM","Associate Professor",[41],{"name":42,"class":43},"Edwards Lifesciences","INDUSTRY","100574266","clinical-outcomes-of-edwards-lifesciences-mitris-reslila-mitral-valve-in-the-asian-population-100574266",false,"NCT06757049","Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population","Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population(THE KOREA MITRIS REGISTRY)","KOREA MITRIS","Inclusion Criteria:\n\n1. Age 19 or older\n2. Requires mitral valve replacement due to mitral valve dysfunction\n3. The participant or their guardian can provide a written consent form approved by the IRB and agree to the research protocol and clinical follow-up schedule.\n\nExclusion Criteria:\n\n1. Life expectancy of less than one year due to causes other than cardiovascular disease\n2. High-risk candidates for mitral valve replacement: Society of Thoracic Surgeons Predicted Risk of Mortality 10% or greater; EuroSCORE 10% or greater; estimated surgical mortality rate by the surgeon 10% or greater\n3. Chronic kidney disease: eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n4. Undergoing surgery for infective endocarditis","ALL","19 Years",{"count":55,"type":56},200,"ESTIMATED","60 Months","OBSERVATIONAL","The purpose of this study is to evaluate the early and mid-term safety and performance of the MITRIS RESILIA mitral valve in Asian patients in a real-world setting",[61],"Mitral Valve Insufficiency",[63],"Mitral Valve Replacement","2024-12-26",{"date":66,"type":67},"2025-01-03","ACTUAL",{"date":69,"type":67},"2024-12-20",{"date":71,"type":56},"2031-03-31",{"name":5,"class":6},1]